Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cognizant Technology Solutions Corp (CTSH) vs Novo Nordisk A/S (NVO) Price & Performance

Cognizant Technology Solutions CorpTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Cognizant Technology Solutions Corp vs Novo Nordisk A/S — how do they compare? Cognizant Technology Solutions Corp trades at $57.78 (market cap $26.40B), while Novo Nordisk A/S trades at $46.26 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 7.9× Cognizant Technology Solutions Corp's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.

CTSHNVO
Market Cap
$26.40B$207.85B
Sector
TechnologyHealth
52-Week High
$86.70$63.98
52-Week Low
$38.73$35.29
Enterprise Value
$27.44B$222.55B
Dividend Yield
2.25%3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cognizant Technology Solutions Corp

CTSH trades at $58.31, up 1.11% today, near its consensus price target of $59.92. The stock shows bullish technical signals with moving averages supporting an uptrend, though oscillators indicate overbought conditions. Recent Q2 2026 earnings missed estimates, but revenue beat expectations, and the company maintains strong profitability with a net margin of 10.26%. AI initiatives and financial services growth are key drivers, as highlighted in recent earnings calls (Seeking Alpha, 2026-07-29).

Outlook: CTSH offers value with a P/E of 12.58 and stable cash flows, but faces risks from client spending caution and competitive pressures. Upside potential exists if AI investments yield growth, though macroeconomic headwinds could limit near-term gains. Analysts are mixed, with 43% recommending buy.

Novo Nordisk A/S

NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.

The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cognizant Technology Solutions Corp

Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.

Read more on CTSH

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO